Thursday, September 17, 2015

Alector Taps Into $32M For Treating Alzheimer's

San Francisco-based biotech Alector has raised $32M in a Series C funding, to help fund its treatments for Alzheimer's disease and other neurodegenerative disorders, the company said Wednesday. The funding came from MRL Ventures, and also included OrbiMed, Polaris Partners, Google Ventures, Topspin Partners, Mission Bay Capital and others. Alector was foundd by Dr. Asa Abeliovich. The company's immuno-modulatory therapies use antibodies to treat Alzheimer's disease and other forms of dementia and neurodegeneration.